Digital Trials Digest, our quarterly newsletter
When it comes to clinical trials, DCT and digital therapeutic (DTx) companies are natural partners. Both are tech savvy and adept in digital health
Decentralized clinical trials offer an effective avenue to mitigate the issues that typify pediatric clinical trials, including patient-reported data accuracy.
Though incidences of pneumonia have decreased overall, the disease is the leading infectious cause of death in children globally, affecting 1 in 6 child deaths.
In our conversations with trial sponsors, ObvioHealth often tackles common misconceptions about decentralized clinical trials (DCTs). These myths hinder our industry’s evolution by keeping sponsors from designing optimal trials that deliver better data with higher retention and compliance rates.
One of the keys to optimizing ePRO is deploying artificial intelligence (AI) to support human participants and clinical teams.
The unique challenges associated with women’s health, and women as a cohort, make clinical research in this sector especially difficult. DCTs are helping to tackle the obstacles.
eConsent can mitigate these shortcomings by providing flexibility and engagement that empower patients with information and sponsors with data integrity.
Diversity in clinical trials is a scientific imperative, a moral and ethical necessity—and a longstanding challenge in clinical research. DCTs are evolving the industry status quo.
Combining the ease of ePRO with expert rating—patient convenience with the objectivity of experts—facilitates more accurate data collection.